Video

Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia (CLL).

During the 2021 ASCO Annual Meeting, findings from a first-in-human study of the novel BCL-2 inhibitor lisaftoclax were presented, demonstrating an 80% overall response rate in patients with relapsed/refractory CLL and small lymphocytic lymphoma.

Regarding safety, no dose-limiting toxicities were observed with up to 1,200 mg/day of lisaftoclax, says Ailawadhi. Any-grade adverse effects (AEs) were observed in 75% of patients and consisted of fatigue (n = 10; 27.8%), neutropenia (n = 8; 22.2%), diarrhea (n = 7; 19.4%), anemia (n = 6; 16.7%), constipation (n = 4; 11.1%), and nausea (n = 4; 11.1%), Ailawadhi explains. Grade 3 or higher AEs were rare and included neutropenia (n = 5; 13.9%), nausea (n = 2; 5.6%), and decreased platelet counts (n = 2; 5.6%).

Notably, no cases of laboratory or clinical tumor lysis syndrome were observed with lisaftoclax, Ailawadhi says. This suggests that lisaftoclax could offer patients a novel treatment approach that doesn’t require hospitalization or slow dose-escalation, concludes Ailawadhi.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity